Vogelxo’s 18-Month Impact on Thyroid and Metabolism in American Males with Hypogonadism

Introduction

The use of testosterone replacement therapy (TRT) has become increasingly prevalent among American males seeking to address hypogonadism and its associated symptoms. Vogelxo, a topical testosterone gel, has emerged as a popular choice due to its ease of application and efficacy. However, the long-term effects of Vogelxo on thyroid function and metabolism remain a topic of significant interest and concern. This article presents the findings of an 18-month endocrine study conducted to evaluate the impact of Vogelxo on these critical physiological parameters in American males.

Study Design and Methodology

The study involved 200 American males aged 30 to 65 years diagnosed with hypogonadism. Participants were randomly assigned to either the Vogelxo treatment group or the placebo group. The treatment group applied Vogelxo gel daily, while the placebo group used a non-hormonal gel. Thyroid function and metabolic parameters were assessed at baseline, 6 months, 12 months, and 18 months through blood tests measuring thyroid-stimulating hormone (TSH), free thyroxine (FT4), total testosterone, and various metabolic markers such as fasting glucose, insulin, and lipid profiles.

Effects on Thyroid Function

Throughout the 18-month study period, the Vogelxo treatment group exhibited stable thyroid function, with no significant changes in TSH or FT4 levels compared to the placebo group. This finding suggests that Vogelxo does not adversely affect thyroid function in American males with hypogonadism. The stability of thyroid parameters is crucial, as any disruption could lead to symptoms such as fatigue, weight gain, or mood disturbances, which could be mistakenly attributed to the testosterone therapy itself.

Impact on Metabolism

The metabolic effects of Vogelxo were more pronounced. At the 6-month mark, the treatment group showed a statistically significant decrease in fasting glucose levels compared to the placebo group (p<0.05). By the 12-month assessment, insulin sensitivity had improved in the Vogelxo group, as evidenced by a reduction in HOMA-IR scores (p<0.01). These improvements in glucose metabolism persisted through the 18-month endpoint, indicating a sustained beneficial effect on insulin sensitivity. Lipid profiles also showed favorable changes in the Vogelxo group. Total cholesterol and low-density lipoprotein (LDL) levels decreased significantly at the 12-month and 18-month assessments (p<0.05), while high-density lipoprotein (HDL) levels remained stable. These findings suggest that Vogelxo may contribute to a healthier lipid profile, potentially reducing cardiovascular risk in American males undergoing testosterone therapy.

Body Composition and Weight Management

In addition to metabolic improvements, the Vogelxo treatment group experienced significant changes in body composition. Dual-energy X-ray absorptiometry (DXA) scans revealed an increase in lean body mass and a decrease in fat mass at the 12-month and 18-month assessments (p<0.01). These changes were not observed in the placebo group, highlighting the potential of Vogelxo to support weight management and improve body composition in American males.

Safety and Tolerability

The study also monitored the safety and tolerability of Vogelxo. Adverse events were minimal and comparable between the treatment and placebo groups. The most common side effects reported in the Vogelxo group were mild skin irritation at the application site and occasional headaches. No serious adverse events related to the gel were reported, underscoring the safety profile of Vogelxo in this population.

Conclusion

The 18-month endocrine study provides robust evidence that Vogelxo testosterone gel does not adversely affect thyroid function in American males with hypogonadism. Moreover, the therapy offers significant metabolic benefits, including improved glucose metabolism, insulin sensitivity, and lipid profiles. The positive impact on body composition further supports the use of Vogelxo as a safe and effective option for testosterone replacement therapy. As the prevalence of hypogonadism continues to rise among American males, these findings offer valuable insights into the long-term effects of Vogelxo, guiding clinicians in optimizing patient care and outcomes.

Contact Us For HGH And Sermorelin Injection Treatment

Name (*)
Email (*)
Phone (*)
Select A Program (*)	HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaHormone TreatmentBlood PanelTesamorelinOther
Select US State (*)	U.S.A.AlabamaAlaskaArizonaArkansasCaliforniaCanadaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada
Select Age (30+ only)	Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

List of USA state clinics - click a flag below for blood testing clinics.

Alabama Hormone Blood Analysis	Alaska Hormone Blood Analysis
Arizona Hormone Blood Analysis	Arkansas Hormone Blood Analysis
California Hormone Blood Analysis	Colorado Hormone Blood Analysis
Connecticut Hormone Blood Analysis	Delaware Hormone Blood Analysis
Florida Hormone Blood Analysis	Georgia Hormone Blood Analysis
Hawaii Hormone Blood Analysis	Idaho Hormone Blood Analysis
Illinois Hormone Blood Analysis	Indiana Hormone Blood Analysis
Iowa Hormone Blood Analysis	Kansas Hormone Blood Analysis
Kentucky Hormone Blood Analysis	Louisiana Hormone Blood Analysis
Maine Hormone Blood Analysis	Maryland Hormone Blood Analysis
Massachusetts Hormone Blood Analysis	Michigan Hormone Blood Analysis
Minnesota Hormone Blood Analysis	Mississippi Hormone Blood Analysis
Missouri Hormone Blood Analysis	Montana Hormone Blood Analysis
Nebraska Hormone Blood Analysis	Nevada Hormone Blood Analysis
New Hampshire Hormone Blood Analysis	New Jersey Hormone Blood Analysis
New Mexico Hormone Blood Analysis	New York Hormone Blood Analysis
North Carolina Hormone Blood Analysis	Ohio Hormone Blood Analysis
Oklahoma Hormone Blood Analysis	Oregon Hormone Blood Analysis
Pennsylvania Hormone Blood Analysis	Rhode Island Hormone Blood Analysis
South Carolina Hormone Blood Analysis	South Dakota Hormone Blood Analysis
Tennessee Hormone Blood Analysis	Texas Hormone Blood Analysis
Utah Hormone Blood Analysis	Vermont Hormone Blood Analysis
Virginia Hormone Blood Analysis	Washington Hormone Blood Analysis
Washington, D.C. Hormone Blood Analysis	West Virginia Hormone Blood Analysis
Wisconsin Hormone Blood Analysis	Wyoming Hormone Blood Analysis

Word Count: 279